Results 81 to 90 of about 14,668 (165)
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino +13 more
wiley +1 more source
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman +4 more
wiley +1 more source
Abstract Background CD47‐targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC‐002 is a novel anti‐CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized.
Tae‐Shin Kim +5 more
wiley +1 more source
Risque infectieux associé au daratumumab en traitement du myélome
Le daratumumab, anticorps monoclonal ciblant le CD38, fait partie des nouvelles thérapies ayant transformé l'approche thérapeutique du myélome ces dernières années, mais son impact sur l'immunité et le risque infectieux reste incertain.
Lacroix, Mathilde
core +1 more source
Abstract Background Human monoclonal (MoAb) anti‐CD38 antibodies, such as daratumumab, are used to treat diseases such as multiple myeloma. Because red blood cells (RBCs) express CD38, these MoAbs interfere with antibody screening and crossmatching in blood banks.
Ayda Javanbakht +3 more
wiley +1 more source
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Key PointsNo new safety signals were observed with daratumumab plus pomalidomide and dexamethasone, except for increased neutropenia. Daratumumab plus pomalidomide and dexamethasone induced rapid, deep, and durable responses in heavily treated patients ...
Nushmia Z. Khokhar +15 more
core +1 more source
Daratumumab for Immunoglobulin Light Chain Amyloidosis
Immunoglobulin light chain (AL) amyloidosis is characterized by small, indolent plasma cell clones that uniformly demonstrate high expression of CD38 surface molecule and produce toxic, free light chains.
Theodorakakou, Foteini +2 more
core +1 more source
British Journal of Haematology, Volume 209, Issue 5, Page 2316-2320, November 2026.
Runfeng Zhang +15 more
wiley +1 more source
Response to daratumumab-retreatment in patients with multiple myeloma
Daratumumab is an effective therapy in multiple myeloma (MM). We assessed whether daratumumab retreatment may re-induce significant responses and which patients do benefit the most.
Ihorst, Gabriele +4 more
core +1 more source

